IL253402A0 - Benzodiazepine dimers, their conjugates, and methods of preparation and use - Google Patents
Benzodiazepine dimers, their conjugates, and methods of preparation and useInfo
- Publication number
- IL253402A0 IL253402A0 IL253402A IL25340217A IL253402A0 IL 253402 A0 IL253402 A0 IL 253402A0 IL 253402 A IL253402 A IL 253402A IL 25340217 A IL25340217 A IL 25340217A IL 253402 A0 IL253402 A0 IL 253402A0
- Authority
- IL
- Israel
- Prior art keywords
- conjugates
- making
- methods
- benzodiazepine dimers
- benzodiazepine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562103157P | 2015-01-14 | 2015-01-14 | |
| US201562215928P | 2015-09-09 | 2015-09-09 | |
| PCT/US2016/013136 WO2016115191A1 (en) | 2015-01-14 | 2016-01-13 | Benzodiazepine dimers, conjugates thereof, and methods of making and using |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL253402A0 true IL253402A0 (en) | 2017-09-28 |
Family
ID=55305072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL253402A IL253402A0 (en) | 2015-01-14 | 2017-07-10 | Benzodiazepine dimers, their conjugates, and methods of preparation and use |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US9527871B2 (https=) |
| EP (1) | EP3245213B1 (https=) |
| JP (1) | JP6498773B2 (https=) |
| KR (1) | KR20170102980A (https=) |
| CN (1) | CN107428780B (https=) |
| AU (1) | AU2016206798A1 (https=) |
| BR (1) | BR112017014599A2 (https=) |
| CA (1) | CA2973354A1 (https=) |
| CL (1) | CL2017001824A1 (https=) |
| CO (1) | CO2017008078A2 (https=) |
| EA (1) | EA201791550A1 (https=) |
| ES (1) | ES2783624T3 (https=) |
| IL (1) | IL253402A0 (https=) |
| MX (1) | MX2017009145A (https=) |
| PE (1) | PE20171184A1 (https=) |
| SG (1) | SG11201705646XA (https=) |
| TW (1) | TW201632531A (https=) |
| WO (1) | WO2016115191A1 (https=) |
| ZA (1) | ZA201704738B (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6676058B2 (ja) * | 2015-01-14 | 2020-04-08 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ヘテロアリーレン架橋したベンゾジアゼピン二量体、そのコンジュゲート、ならびに製造および使用方法 |
| US9504694B2 (en) * | 2015-03-19 | 2016-11-29 | Cellerant Therapeutics, Inc. | Isoquinolidinobenzodiazepines |
| WO2018048975A1 (en) | 2016-09-09 | 2018-03-15 | Bristol-Myers Squibb Company | Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment |
| WO2018053552A2 (en) * | 2016-09-19 | 2018-03-22 | Cellerant Therapeutics, Inc. | Isoquinolidinobenzodiazepines |
| KR20190075084A (ko) * | 2016-10-10 | 2019-06-28 | 셀러랜트 세라퓨틱스 인코퍼레이티드 | 이소퀴놀리디노벤조디아제핀 (iqb)-1-(클로로메틸)-2,3-디히드로-1h-벤조[e]인돌 (cbi) 이량체 |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
| US10398783B2 (en) | 2016-10-20 | 2019-09-03 | Bristol-Myers Squibb Company | Antiproliferative compounds and conjugates made therefrom |
| EP4148044A1 (en) | 2017-01-25 | 2023-03-15 | ImmunoGen, Inc. | Methods of preparing cytotoxic benzodiazepine derivatives |
| WO2018195243A1 (en) * | 2017-04-20 | 2018-10-25 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives and conjugates thereof |
| CN111278461A (zh) | 2017-08-16 | 2020-06-12 | 百时美施贵宝公司 | 可前药化抗体、其前药以及使用和制备方法 |
| GB201714115D0 (en) | 2017-09-04 | 2017-10-18 | Femtogenix Ltd | Cytotoxic agents |
| IL301637B2 (en) | 2017-09-29 | 2024-10-01 | Daiichi Sankyo Co Ltd | Antibody-pyrrolobenzodiazepine derivative conjugate |
| MX2020012718A (es) * | 2018-05-29 | 2021-02-16 | Intocell Inc | Derivados de benzodiazepinas novedosos y usos de los mismos. |
| KR20210068591A (ko) | 2018-10-31 | 2021-06-09 | 주식회사 인투셀 | 융합된 헤테로시클릭 벤조디아제핀 유도체 및 그의 용도 |
| JP7401456B2 (ja) | 2018-11-14 | 2023-12-19 | 第一三共株式会社 | 抗ｃｄｈ６抗体－ピロロベンゾジアゼピン誘導体コンジュゲート |
| ES2943474T3 (es) | 2018-11-30 | 2023-06-13 | Bristol Myers Squibb Co | Anticuerpo que comprende una extensión carboxiterminal de una cadena ligera que contiene glutamina, conjugados del mismo, y métodos y usos |
| KR20210102334A (ko) | 2018-12-12 | 2021-08-19 | 브리스톨-마이어스 스큅 컴퍼니 | 트랜스글루타미나제 접합을 위해 변형된 항체, 그의 접합체, 및 방법 및 용도 |
| GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
| AU2020246448A1 (en) | 2019-03-25 | 2021-10-14 | Daiichi Sankyo Company, Limited | Anti-HER2 antibody-pyrrolobenzodiazepine derivative conjugate |
| EP3950061A4 (en) | 2019-03-25 | 2022-11-16 | Daiichi Sankyo Company, Limited | ANTIBODY PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE |
| TWI841715B (zh) | 2019-03-27 | 2024-05-11 | 日商第一三共股份有限公司 | 抗體-吡咯并苯二氮呯衍生物結合物及ｐａｒｐ抑制劑之組合及其用途 |
| US20220251206A1 (en) | 2019-06-11 | 2022-08-11 | Bristol-Myers Squibb Company | Anti-ctla4 antibody prodruggable (probody) at a cdr position |
| WO2021055306A1 (en) | 2019-09-16 | 2021-03-25 | Bristol-Myers Squibb Company | Dual capture method for analysis of antibody-drug conjugates |
| CA3204628A1 (en) | 2021-01-13 | 2022-07-21 | John T. POIRIER | Antibody-pyrrolobenzodiazepine derivative conjugate |
| CN113372245B (zh) * | 2021-06-17 | 2023-01-13 | 仪征市海帆化工有限公司 | 一种n-苯甲酰基-o,o-对甲苯磺酰基-二乙醇胺的合成方法 |
| WO2023037237A1 (en) * | 2021-09-09 | 2023-03-16 | Wavelength Enterprises Ltd | Process for the preparation of remimazolam |
| KR20240073035A (ko) * | 2021-09-30 | 2024-05-24 | 아지노모토 가부시키가이샤 | 항체 및 기능성 물질의 컨쥬게이트 또는 그 염, 및 그 제조에 사용되는 항체 유도체 및 화합물 또는 그 염 |
| IL312728A (en) | 2021-11-30 | 2024-07-01 | Daiichi Sankyo Co Ltd | Protease-cleavable masked antibodies |
| US20250170255A1 (en) | 2022-02-09 | 2025-05-29 | Daiichi Sankyo Company, Limited | Environmentally-responsive masked antibody and use thereof |
| WO2025214466A1 (en) * | 2024-04-12 | 2025-10-16 | BeiGene Guangzhou Biologics Manufacturing Co., Ltd. | Targeted pyrrolobenzodiazapine conjugates |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69930328T2 (de) | 1998-08-27 | 2006-12-14 | Spirogen Ltd., Ryde | Dimere Pyrrolobenzodiazepine |
| SI1545613T1 (sl) | 2002-07-31 | 2011-11-30 | Seattle Genetics Inc | Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni |
| GB0226593D0 (en) | 2002-11-14 | 2002-12-24 | Consultants Ltd | Compounds |
| GB0416511D0 (en) | 2003-10-22 | 2004-08-25 | Spirogen Ltd | Pyrrolobenzodiazepines |
| SI2270010T1 (sl) | 2004-03-01 | 2012-05-31 | Spirogen Ltd | hidroksi H pirolo c benzodiazepin onski derivati kot ključni intermediati za pripravo C substituiranih pirolobenzodiazepinov |
| GB0404577D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
| GB0404578D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
| JP5166861B2 (ja) | 2004-03-09 | 2013-03-21 | スピロゲン リミティッド | ピロロベンゾジアゼピン |
| PL1879901T3 (pl) | 2005-04-21 | 2010-06-30 | Medimmune Ltd | Pirolobenzodiazepiny |
| CA2623236A1 (en) | 2005-09-26 | 2007-04-05 | Medarex, Inc. | Human monoclonal antibodies to cd70 |
| US8383118B2 (en) | 2005-12-08 | 2013-02-26 | Medarex, Inc. | Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1 |
| SI1813614T1 (sl) | 2006-01-25 | 2012-01-31 | Sanofi 174 | Citotoksična sredstva, ki obsegajo nove tomajmicinske derivate |
| KR101570252B1 (ko) | 2007-07-17 | 2015-11-19 | 메다렉스, 엘.엘.시. | 글리피칸-3에 대한 단클론 항체 |
| PL2019104T3 (pl) | 2007-07-19 | 2014-03-31 | Sanofi Sa | Środki cytotoksyczne obejmujące nowe pochodne tomaymycyny i ich zastosowanie terapeutyczne |
| CA2700860C (en) | 2007-10-01 | 2016-07-19 | Jonathan A. Terrett | Human antibodies that bind mesothelin, and uses thereof |
| GB0813432D0 (en) | 2008-07-22 | 2008-08-27 | Spirogen Ltd | Pyrrolobenzodiazepines |
| GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
| CN102365021B (zh) | 2009-02-05 | 2015-07-15 | 伊缪诺金公司 | 新型苯并二氮杂*衍生物 |
| FR2949469A1 (fr) | 2009-08-25 | 2011-03-04 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application en therapeutique |
| DK2528625T3 (da) | 2010-04-15 | 2013-10-14 | Spirogen Sarl | Pyrrolobenzodiazepiner og konjugater deraf |
| US8697688B2 (en) | 2010-04-15 | 2014-04-15 | Seattle Genetics Inc. | Pyrrolobenzodiazepines used to treat proliferative diseases |
| MX391454B (es) | 2010-04-15 | 2025-03-05 | Seagen Inc | Compuesto de engarce-fármaco para conjugación a una unidad de ligando. |
| FR2963007B1 (fr) | 2010-07-26 | 2013-04-05 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application therapeutique |
| JP6049642B2 (ja) * | 2011-02-15 | 2016-12-21 | イミュノジェン・インコーポレーテッド | 複合体の調製方法 |
| JP6170494B2 (ja) | 2011-09-20 | 2017-07-26 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピン |
| JP6104257B2 (ja) | 2011-10-14 | 2017-03-29 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピンおよびそのコンジュゲート |
| CN103998449A (zh) | 2011-10-14 | 2014-08-20 | 斯皮罗根有限公司 | 吡咯并苯并二氮杂卓 |
| CA2850103C (en) | 2011-10-14 | 2019-09-10 | Spirogen Sarl | Pyrrolobenzodiazepines |
| WO2013055993A1 (en) | 2011-10-14 | 2013-04-18 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| ES2945932T3 (es) | 2011-10-14 | 2023-07-10 | Seagen Inc | Pirrolobenzodiazepinas y conjugados dirigidos |
| WO2013177481A1 (en) * | 2012-05-25 | 2013-11-28 | Immunogen, Inc. | Benzodiazepines and conjugates thereof |
| HK1211208A1 (zh) | 2012-08-22 | 2016-05-20 | Immunogen, Inc. | 細胞毒性苯並二氮呯衍生物 |
| AU2013328674B2 (en) | 2012-10-12 | 2017-06-22 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| CN104837502B (zh) | 2012-10-12 | 2018-08-10 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓及其结合物 |
| US10131682B2 (en) | 2012-11-24 | 2018-11-20 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules |
| CN105246894A (zh) | 2012-12-21 | 2016-01-13 | 斯皮罗根有限公司 | 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物 |
| CN105189507A (zh) | 2012-12-21 | 2015-12-23 | 斯皮罗根有限公司 | 吡咯并苯并二氮杂卓及其结合物 |
| NZ710746A (en) | 2013-03-13 | 2018-11-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| SG11201507214SA (en) | 2013-03-13 | 2015-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| CA2905181C (en) | 2013-03-13 | 2020-06-02 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy |
| US20160106861A1 (en) | 2013-04-26 | 2016-04-21 | Spirogen Sarl | Axl antibody-drug conjugate and its use for the treatment of cancer |
-
2016
- 2016-01-13 TW TW105100987A patent/TW201632531A/zh unknown
- 2016-01-13 SG SG11201705646XA patent/SG11201705646XA/en unknown
- 2016-01-13 CA CA2973354A patent/CA2973354A1/en not_active Abandoned
- 2016-01-13 EP EP16703196.2A patent/EP3245213B1/en active Active
- 2016-01-13 PE PE2017001216A patent/PE20171184A1/es unknown
- 2016-01-13 BR BR112017014599A patent/BR112017014599A2/pt not_active Application Discontinuation
- 2016-01-13 US US14/994,296 patent/US9527871B2/en active Active
- 2016-01-13 MX MX2017009145A patent/MX2017009145A/es unknown
- 2016-01-13 WO PCT/US2016/013136 patent/WO2016115191A1/en not_active Ceased
- 2016-01-13 AU AU2016206798A patent/AU2016206798A1/en not_active Abandoned
- 2016-01-13 KR KR1020177022244A patent/KR20170102980A/ko not_active Ceased
- 2016-01-13 EA EA201791550A patent/EA201791550A1/ru unknown
- 2016-01-13 JP JP2017537227A patent/JP6498773B2/ja not_active Expired - Fee Related
- 2016-01-13 CN CN201680006151.5A patent/CN107428780B/zh not_active Expired - Fee Related
- 2016-01-13 ES ES16703196T patent/ES2783624T3/es active Active
- 2016-11-15 US US15/351,843 patent/US9676794B2/en active Active
-
2017
- 2017-05-05 US US15/587,715 patent/US9822144B2/en active Active
- 2017-07-10 IL IL253402A patent/IL253402A0/en unknown
- 2017-07-13 CL CL2017001824A patent/CL2017001824A1/es unknown
- 2017-07-13 ZA ZA2017/04738A patent/ZA201704738B/en unknown
- 2017-08-10 CO CONC2017/0008078A patent/CO2017008078A2/es unknown
- 2017-10-17 US US15/785,675 patent/US10112975B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20180079781A1 (en) | 2018-03-22 |
| US20160200742A1 (en) | 2016-07-14 |
| SG11201705646XA (en) | 2017-08-30 |
| JP6498773B2 (ja) | 2019-04-10 |
| CN107428780B (zh) | 2020-09-04 |
| US20170233436A1 (en) | 2017-08-17 |
| EP3245213B1 (en) | 2020-03-04 |
| ZA201704738B (en) | 2019-02-27 |
| CO2017008078A2 (es) | 2017-11-10 |
| CN107428780A (zh) | 2017-12-01 |
| ES2783624T3 (es) | 2020-09-17 |
| KR20170102980A (ko) | 2017-09-12 |
| MX2017009145A (es) | 2017-11-22 |
| US9822144B2 (en) | 2017-11-21 |
| CL2017001824A1 (es) | 2018-02-09 |
| AU2016206798A1 (en) | 2017-08-31 |
| US20170073357A1 (en) | 2017-03-16 |
| PE20171184A1 (es) | 2017-08-22 |
| WO2016115191A1 (en) | 2016-07-21 |
| CA2973354A1 (en) | 2016-07-21 |
| BR112017014599A2 (pt) | 2018-01-16 |
| TW201632531A (zh) | 2016-09-16 |
| JP2018503639A (ja) | 2018-02-08 |
| US10112975B2 (en) | 2018-10-30 |
| EP3245213A1 (en) | 2017-11-22 |
| US9527871B2 (en) | 2016-12-27 |
| EA201791550A1 (ru) | 2017-11-30 |
| US9676794B2 (en) | 2017-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201704738B (en) | Benzodiazepine dimers, conjugates thereof, and methods of making and using | |
| ZA201704739B (en) | Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using | |
| HUS2500022I1 (hu) | Terápiás ellenanyagok és alkalmazásaik | |
| ZA201706040B (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
| ZA201705935B (en) | Cd48 antibodies and conjugates thereof | |
| IL272924A (en) | Methods for preparing and using endoxifen | |
| IL252430A0 (en) | Antibodies, uses and methods | |
| IL256462A (en) | Benzodiazepine macrocyclic dimers, conjugates, their preparation and uses | |
| ZA201704640B (en) | Silybin injection and preparation method therefor | |
| IL244857A0 (en) | A fusion protein of acetylcholinesterase and the fc region | |
| HK1245788A1 (en) | Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using | |
| HK1245787A1 (en) | Benzodiazepine dimers, conjugates thereof, and methods of making and using | |
| AP2016001094S (en) | A-1 | |
| AU2015316V (en) | SUPA2221 Argyranthemum frutescens | |
| AU2015021V (en) | SUPA2220 Argyranthemum frutescens | |
| AU2015022V (en) | SUPA2235 Argyranthemum frutescens | |
| AU2015019V (en) | SUPA2101 Argyranthemum frutescens |